article thumbnail

Amyloidosis Drug Improves Outcomes, Survival

Med Page Today

(MedPage Today) -- LONDON -- Vutrisiran (Amvuttra) improved functional and disease outcomes as well as survival in transthyretin amyloidosis cardiomyopathy (ATTR-CM), according to findings from the HELIOS-B phase III trial. And the benefits.

Outcomes 106
article thumbnail

Finerenone improves outcomes in HFmrEF and HFpEF

Nature Reviews - Cardiology

Nature Reviews Cardiology, Published online: 19 September 2024; doi:10.1038/s41569-024-01087-x The non-steroidal mineralocorticoid receptor antagonist finerenone reduces the risk of adverse outcomes in patients with heart failure with mildly reduced ejection fraction or with preserved ejection fraction, according to findings presented at the ESC Congress (..)

article thumbnail

Outcomes of Class Switching vs Cycling TNF Inhibitors

HCPLive

Panelists discuss how switching to a biologic with a different mechanism of action can enhance clinical outcomes in patients with inadequate responses to tumor necrosis factor inhibitors.

article thumbnail

After Adverse Pregnancy Outcomes, Mortality Risk Lingers for Decades

Med Page Today

(MedPage Today) -- Women who experienced major adverse pregnancy outcomes still had increased mortality risks decades later, a population-based cohort study of Swedish data found. Adverse pregnancy outcomes independently associated with increased.

Outcomes 120
article thumbnail

Artificial blood vessels could improve heart bypass outcomes

Science Daily - Heart Disease

Strong, flexible, gel-like tubes -- created using a novel 3D printing technology -- could improve outcomes for heart bypass patients by replacing the human and synthetic veins currently used in surgery to re-route blood flow, experts say.

Outcomes 100
article thumbnail

Artificial blood vessels could improve heart bypass outcomes

Medical Xpress - Cardiology

Strong, flexible, gel-like tubes—created using a novel 3D printing technology—could improve outcomes for heart bypass patients by replacing the human and synthetic veins currently used in surgery to re-route blood flow, experts say.

Outcomes 101
article thumbnail

Deucravacitinib Superior to Apremilast in Patient-Reported Outcomes for Psoriasis

HCPLive

In this analysis, investigators compared deucravacitinib in terms of patient-reported outcomes versus those of placebo and apremilast.